医学
颈淋巴结清扫术
比例危险模型
口腔颌面外科
内科学
危险系数
肿瘤科
基底细胞
生存分析
子群分析
外科
癌
置信区间
作者
Qiuyu Wu,Yuanhang Xia,Ling Qiu,Shuqiong Wen,Qunxing Li,Gao Xiang,Wen-Rong Jiang,Tao Wang,Ping Ji,Zhanpeng Ou
标识
DOI:10.1186/s12903-023-03632-5
摘要
Abstract Background The neck management of clinical-nodal negative (cN0) oral squamous cell carcinoma (OSCC) remains controversial. Elective neck dissection (END) and observation are the main strategies, but it is still not clear who could benefit the most from END. The purpose of this study was to clarify the potential clinical factors that affect the therapeutic value of END and to explore the actual characteristics associated with benefit from END. Methods Patients with cN0 OSCC were identified in the SEER database from 2000 to 2019. 5-year Overall survival (OS) and disease-specific survival (DSS) were analyzed using the Kaplan‒Meier method, and the hazard ratios (HRs) for survival were estimated using the Cox regression model. Multiple subgroup analyses of DSS and OS among different factors, comparing END and No END, were performed. Results A total of 17,019 patients with cN0 OSCC were included. The basic survival analysis and Cox regression model showed that END increased the probability of 5-year DSS and OS and was an independent prognostic factor. However, among patients who underwent only primary tumor surgery, no significant differences were found between the END and No END groups in 5-year DSS ( P = 0. 585) and OS ( P = 0.465). Further subgroup analysis showed that primary sites and T stage, but not other factors, might influence the benefit of END. Significant differences were found for T1 ( P < 0.001 for OS) and T2 ( P = 0.001 for DSS and < 0.001 for OS) tongue squamous cell carcinoma (TSCC) but not for other primary tumor sites. Conclusion This large-scale retrospective population-based cohort study suggests that not all patients with cN0 OSCC could benefit from END. Patients with cN0 TSCC are recommended to undergo END, especially with early-stage tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI